<DOC>
	<DOC>NCT01796301</DOC>
	<brief_summary>This is a multi-center, randomized, open-label, TPTD-controlled study in postmenopausal women with osteoporosis at high risk for fracture.</brief_summary>
	<brief_title>An Open-label Study to Evaluate the Effect of Treatment With AMG 785 or Teriparatide in Postmenopausal Women (STRUCTURE)</brief_title>
	<detailed_description>This is a multi-center, randomized, open-label, TPTD-controlled study in postmenopausal women with osteoporosis at high risk for fracture.</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis, Postmenopausal</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>Postmenopausal women, aged ≥ 60 to ≤ 90. Received oral bisphosphonate therapy for at least 3 years immediately prior to screening BMD Tscore ≤ 2.50 at the lumbar spine, total hip or femoral neck History of nonvertebral fracture after age 50, or vertebral fracture. Use of other agents affecting bone metabolism including Strontium ranelate, fluoride (for osteoporosis), odanacatib (MK0822) or any other cathepsin K inhibitor, IV bisphosphonates, Denosumab, TPTD or any PTH analogs, Systemic oral or transdermal estrogen, SERMs, activated vitamin D3, vitamin K2, calcitonin, Tibolone, cinacalcet, Systemic glucocorticosteroids: History of metabolic or bone disease (except osteoporosis) that may interfere with the interpretation of study results, such as sclerosteosis, Paget's disease, rheumatoid arthritis, osteomalacia, osteogenesis imperfecta, osteopetrosis, ankylosing spondylitis, Cushing's disease, hyperprolactinemia, and malabsorption syndrome Vitamin D insufficiency, defined as 25 (OH) vitamin D levels &lt; 20 ng/mL, as determined by the central laboratory. Current hyper or hypocalcemia Current, uncontrolled hyper or hypothyroidism</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Postmenopausal Osteoporosis</keyword>
</DOC>